May 29, 2026Thrombosis and Haemostasis
Bleeding and Thrombotic Trade-off in Dual-Risk Patients Undergoing Percutaneous Coronary Intervention
View Full Paper
Ask AI
Bookmark
Share
Key result
Provided text contains only editorial board information and no clinical study data.
Why the study?
Managing thrombotic and bleeding risks post-PCI is challenging in patients with both high bleeding risk and high thrombotic risk, requiring better risk characterization to support personalized DAPT management.
Does the ARC trade-off model predict net adverse clinical events in dual-risk patients undergoing percutaneous coronary intervention?
Population
3,051 PCI patients screened, identifying a 12.4% dual-risk subset
Comparison
ARC trade-off model groups DRBR<TR vs DRBR=TR vs DRBR>TR
Design
Cohort study
Follow-up
18 months
Authors
Discussion
Loading...
Member takes
Implication
DRBR>TR stratification was associated with higher NACE after PCI; leaves open whether the ARC trade-off model should guide personalized DAPT.
Structured PICO
Does the ARC trade-off model predict net adverse clinical events in dual-risk patients undergoing percutaneous coronary intervention?
P
Population
3,051 patients who underwent percutaneous coronary intervention (PCI) between November 2019 and December 2023, including a 12.4% subset identified as dual-risk (high bleeding risk by ARC-HBR criteria and high thrombotic risk by ESC criteria).
I
Intervention
Stratification by the Academic Research Consortium (ARC) trade-off model into DRBR>TR (risk of death from bleeding higher than thrombosis) or DRBR<TR (risk of death from bleeding lower than thrombosis) groups.
C
Comparator
DRBR=TR group (risk of death from bleeding similar to thrombosis).
O
Outcome
Net adverse clinical events (NACE), defined as a composite of all-cause death, myocardial infarction (MI), stent thrombosis (ST), or major bleeding at 18 months.composite
The ARC trade-off model successfully stratifies dual-risk PCI patients, identifying those at highest risk for adverse events who may benefit from personalized dual antiplatelet therapy strategies.
Cite This Study
Mauro et al. (2026) studied Dual-Risk Patients Undergoing Percutaneous Coronary Intervention. The provided text contains only the journal's editorial board information and no clinical study data.
Topics
View Full Paper
Ask AI
Bookmark
Share